TY - JOUR
T1 - P300 amplitude during a monetary incentive delay task predicts future therapy completion in individuals with major depressive disorder
AU - White, Evan J.
AU - Nacke, Mariah
AU - Akeman, Elisabeth
AU - Cannon, Mallory J.
AU - Mayeli, Ahmad
AU - Touthang, James
AU - Zoubi, Obada al
AU - McDermott, Timothy J.
AU - Kirlic, Namik
AU - Santiago, Jessica
AU - Kuplicki, Rayus
AU - Bodurka, Jerzy
AU - Paulus, Martin P.
AU - Craske, Michelle G.
AU - Wolitzky-Taylor, Kate
AU - Abelson, James
AU - Martell, Christopher
AU - Clausen, Ashley
AU - Stewart, Jennifer L.
AU - Aupperle, Robin L.
N1 - Funding Information:
Evan J. White Ph.D. receives funding support from the National Institue on Minority Health and Health Disparaties (NIMHD) under award number: K99MD015736. Rayus Kuplicki, Ph.D. Jennifer L. Stewart, Ph.D., Namik Kirlic, Ph.D., Robin Aupperle Ph.D., and Martin Paulus M.D. receive funding from the National Institute of General Medical Sciences (NIGMS) center grant P20GM121312 ; Robin Aupperle Ph.D. has additional grant funding from NIMH (K23MH108707; R01MH123691); and Martin Paulus, M.D. has additional grant funding from the National Institute of Drug Abuse (U01DA041089) and Dr. Paulus is an advisor to Spring Care, Inc., a behavioral health startup, he has received royalties for an article about methamphetamine in UpToDate. Timothy McDermott, M.A., received support from the National Institute of Mental Health under Award Number F31MH122090 .
Funding Information:
Evan J. White Ph.D. receives funding support from the National Institue on Minority Health and Health Disparaties (NIMHD) under award number: K99MD015736. Rayus Kuplicki, Ph.D. Jennifer L. Stewart, Ph.D., Namik Kirlic, Ph.D., Robin Aupperle Ph.D., and Martin Paulus M.D. receive funding from the National Institute of General Medical Sciences (NIGMS) center grant P20GM121312; Robin Aupperle Ph.D. has additional grant funding from NIMH (K23MH108707; R01MH123691); and Martin Paulus, M.D. has additional grant funding from the National Institute of Drug Abuse (U01DA041089) and Dr. Paulus is an advisor to Spring Care, Inc., a behavioral health startup, he has received royalties for an article about methamphetamine in UpToDate. Timothy McDermott, M.A., received support from the National Institute of Mental Health under Award Number F31MH122090.This work has been supported in part by The William K. Warren Foundation. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Funding Information:
Evan J. White Ph.D. receives funding support from the National Institute on Minority Health and Health Disparaties (NIMHD) under award number: K99MD015736. Rayus Kuplicki, Ph.D. Jennifer L. Stewart, Ph.D., Namik Kirlic, Ph.D., Robin Aupperle Ph.D., and Martin Paulus M.D. receive funding from the National Institute of General Medical Sciences (NIGMS) center grant P20GM121312; Robin Aupperle Ph.D. has additional grant funding from NIMH (K23MH108707; R01MH123691); and Martin Paulus, M.D. has additional grant funding from the National Institute of Drug Abuse (U01DA041089). Timothy McDermott, M.A., received support from the National Institute of Mental Health under Award Number F31MH122090. All authors have approved the final manuscript for submission.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Introduction: Treatment effectiveness for major depressive disorder (MDD) is often affected by client non-adherence, dropout, and non-response. Identification of client characteristics predicting successful treatment completion and/or response (i.e., symptom reduction) may be an important tool to increase intervention effectiveness. It is unclear whether neural attenuations in reward processing associated with MDD predict behavioral treatment outcome. Methods: This study aimed to determine whether blunted neural responses to reward at baseline differentiate MDD (n = 60; 41 with comorbid anxiety) and healthy control (HC; n = 40) groups; and predict MDD completion of and response to 7–10 sessions of behavior therapy. Participants completed a monetary incentive delay (MID) task. The N200, P300, contingent negative variation (CNV) event related potentials (ERPs) and behavioral responses (reaction time [RT], correct hits) were quantified and extracted for cross-sectional group analyses. ERPs and behavioral responses demonstrating group differences were then used to predict therapy completion and response within MDD. Results: MDD exhibited faster RT and smaller P300 amplitudes than HC across conditions. Within the MDD group, treatment completers (n = 37) exhibited larger P300 amplitudes than non-completers (n = 21). Limitations: : This study comprises secondary analyses of EEG data; thus task parameters are not optimized to examine feedback ERPs from the paradigm. We did not examine heterogenous presentations of MDD; however, severity and comorbidity did not influence findings. Conclusions: Previous studies suggest that P300 is an index of motivational salience and stimulus resource allocation. In sum, individuals who deploy greater neural resources to task demands are more likely to persevere in behavioral therapy.
AB - Introduction: Treatment effectiveness for major depressive disorder (MDD) is often affected by client non-adherence, dropout, and non-response. Identification of client characteristics predicting successful treatment completion and/or response (i.e., symptom reduction) may be an important tool to increase intervention effectiveness. It is unclear whether neural attenuations in reward processing associated with MDD predict behavioral treatment outcome. Methods: This study aimed to determine whether blunted neural responses to reward at baseline differentiate MDD (n = 60; 41 with comorbid anxiety) and healthy control (HC; n = 40) groups; and predict MDD completion of and response to 7–10 sessions of behavior therapy. Participants completed a monetary incentive delay (MID) task. The N200, P300, contingent negative variation (CNV) event related potentials (ERPs) and behavioral responses (reaction time [RT], correct hits) were quantified and extracted for cross-sectional group analyses. ERPs and behavioral responses demonstrating group differences were then used to predict therapy completion and response within MDD. Results: MDD exhibited faster RT and smaller P300 amplitudes than HC across conditions. Within the MDD group, treatment completers (n = 37) exhibited larger P300 amplitudes than non-completers (n = 21). Limitations: : This study comprises secondary analyses of EEG data; thus task parameters are not optimized to examine feedback ERPs from the paradigm. We did not examine heterogenous presentations of MDD; however, severity and comorbidity did not influence findings. Conclusions: Previous studies suggest that P300 is an index of motivational salience and stimulus resource allocation. In sum, individuals who deploy greater neural resources to task demands are more likely to persevere in behavioral therapy.
KW - Behavioral therapy
KW - Depression
KW - Event-related potential
KW - P300
KW - Treatment outcome
UR - http://www.scopus.com/inward/record.url?scp=85114701532&partnerID=8YFLogxK
U2 - 10.1016/j.jad.2021.08.106
DO - 10.1016/j.jad.2021.08.106
M3 - Article
C2 - 34706458
AN - SCOPUS:85114701532
SN - 0165-0327
VL - 295
SP - 873
EP - 882
JO - Journal of Affective Disorders
JF - Journal of Affective Disorders
ER -